BawejaR, FaraoneSV, ChildressAC, et al.From consensus statement to pills to pixels: New innovations in attention-deficit/hyperactivity disorder care. J Child Adolesc Psychopharmacol, 2024; 34(4):167–182; doi: 10.1089/cap.2024.0022
2.
DinnissenM, DietrichA, BierensM, et al.Long-term effectiveness of off-label risperidone treatment in children and adolescents: A Randomized, Placebo-Controlled Discontinuation Study. J Child Adolesc Psychopharmacol, 2024; 34(6):253–263; doi: 10.1089/cap.2023.0065
3.
FarhatLC, BehlingE, Landeros-WeisenbergerA, et al.Comparative efficacy, tolerability, and acceptability of pharmacological interventions for the treatment of children, adolescents, and young adults with Tourette’s syndrome: A systematic review and network meta-analysis. Lancet Child Adolesc Health, 2023; 7(2):112–126; doi: 10.1016/S2352-4642(22)00316-9
4.
FindlingRL, McNamaraNK, PavuluriM, et al.Lithium for the maintenance treatment of bipolar I disorder: A Double-Blind, Placebo-Controlled Discontinuation Study. J Am Acad Child Adolesc Psychiatry, 2019; 58(2):287–296.e4; doi: 10.1016/j.jaac.2018.07.901
5.
GreenB, WatersA, Jimenez-ShahedJ. Pain in Tourette syndrome: A comprehensive review. J Child Adolesc Psychopharmacol, 2024; doi: 10.1089/cap.2024.0025
6.
OrganistaD, RosewaterJ, BezY, et al.Naltrexone treatment for multiple substance use disorders in an adolescent boy. J Child Adolesc Psychopharmacol, 2024; doi: 10.1089/cap.2024.0033
7.
PlaciniF, BargnesiF, MiloneA, et al.Extended-release lithium sulfate in adolescents with bipolar disorder: Results from a Longitudinal Prospective Cohort Study. J Child Adolesc Psychopharmacol, 2024; doi: 10.1089/cap.2024.0092
8.
ScheinJ, CloutierM, Gauthier-LoiselleM, et al.Quality of life and outcomes associated with adverse effects in pediatric patients with attention-deficit/hyperactivity disorder and their parents/caregivers. J Child Adolesc Psychopharmacol, 2024; doi: 10.1089/cap.2024.0061
9.
StimpflJN, WalkupJT, RobbAS, et al.Deprescribing antidepressants in children and adolescents: A systematic review of discontinuation approaches, cross-titration, and withdrawal symptoms. J Child Adolesc Psychopharmacol, 2024; doi: 10.1089/cap.2024.0099
10.
WalterHJ, AbrightAR, BuksteinOG, et al.Clinical practice guideline for the assessment and treatment of children and adolescents with major and persistent depressive disorders. J Am Acad Child Adolesc Psychiatry, 2023; 62(5):479–502; doi: 10.1016/j.jaac.2022.10.001
